article · Reviews in Inorganic Chemistry
Abstract Enticed by the present scenario of infectious diseases, four new Co(II), Ni(II), Cu(II), and Cd(II) complexes of Schiff base ligand were synthesized from 6,6′-((1E-1′E)(phenazine-2,3-dielbis(azanylidene)-bis-(methanylidene)-bis-(3-(diethylamino)phenol)) ( H 2 L ) to ascertain as effective drug for antituberculosis, anti-inflammatory, antioxidant, cytotoxic and antimicrobial activities. The organic ligand and its metal(II) complexes were characterized by numerous physical and spectroscopic methods, which showed that the complexes have a general formula, [ ML ], (where M = Co(II) ( C1 ), Ni(II) ( C2 ), Cu(II) ( C3 ) and Cd(II) ( C4 )), for metal complexes have been proposed and have a square planar geometry, are amorphous in nature, and are thermally stable. Data highlight obtained from activity testing against tuberculosis, inflammation, and oxidants that all compounds are significantly active against these symptoms. Also, was to evaluate the effectiveness of various compounds against bacterial and fungal strains. Specifically, four bacterial strains ( Bacillus subtilis , Staphylococcus aureus , Escherichia coli , and Pseudomonas aeruginosa ) and two fungal strains ( Aspergillus flavus and Candida albicans ) were tested and compared to the results of some standard drugs. The results revealed that compound C4 was more effective against bacterial strains than the comparison standard drugs. In addition, C3 was found to be the most effective of the comparison antibiotics against fungi, while the other compounds showed moderate antifungal activity. Moreover, to support the vitro results, certain computational studies as molecular docking studies, DFT, MESP, and AMEDT were also conducted to confirm the effectiveness of an organic ligand and its complexes against tuberculosis. These studies revealed that C4 is the most effective against tuberculosis and has desirable effects such as absorption, no degradation and no hepatotoxicity, etc.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1515/revic-2024-0007
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.